A previous open-label trial found that daily con- sumption of YIT10347 improves some subjective psychological symptoms and POMS scores (decreasing “anger–hostility” subscale scores and increasing “vigor” subscale scores) and reduces salivary cortisol levels (Urita et al., 2015). However, we detected no significant differences in the levels or relief rates of these param- eters or gastric emptying in this trial. One reasonable explanation for the differences in results between the 2 trials is that the participants in this trial—all healthy adults—had normal levels of these parameters. Further study is necessary to clarify the effects of YIT10347 on mental parameters and gastric emptying in patients with FGID in a randomized, double-blind, placebo- controlled, parallel comparative trial.